THE DEAL, AT A GLANCE

Astrocyte Pharmaceuticals

4/4 reviewed

Astrocyte Pharmaceuticals

Astrocyte develops AST-004, an experimental drug for concussion, brain injury and stroke recovery.

Astrocyte announced $9.5 million Series B funding, bringing total financing and grants to $40 million.

01What it doesAstrocyte develops AST-004, an experimental drug for concussion, brain injury and stroke recovery.Source-grounded · automated review · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

Astrocyte Pharmaceuticals Inc. has raised…

02Who is involvedDeepWork Capital led; MintPharma, Waterstar, Dynagrow, Angel Star and existing investors participated.Source-grounded · automated review · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

The round was led by…

03What happenedAstrocyte announced $9.5 million Series B funding, bringing total financing and grants to $40 million.Source-grounded · automated review · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

The latest round brings total…

04Why it mattersFunding supports Phase 2 testing of a potential treatment for brain injuries with few current drug options.Interpretation · Explore ↗

Checked 2026-10-02 · Review due 2026-10-09

Read supporting source ↗

The company plans to use…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Astrocyte Pharmaceuticals · Financing Record

Explore source-linked visual explanations for Astrocyte Pharmaceuticals. Unsupported claims are withheld while source review continues.

Record 13084 · Recorded date: 2026-09-30